Background: The aim of this randomized trial was to evaluate the abortion rate of combined regimen of letrozole and misoprostol in second-trimester abortion.
Study Design: This was a randomized, double-blinded, placebo-controlled trial of 130 women requesting legal termination of pregnancy at gestational age between 12 and 20 weeks. Letrozole 7.5 mg or placebo were given for 3 days, followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses on the third day.
Results: The abortion rate in 24 and 48 h were similar for the letrozole and placebo groups (24 h: 93.8% vs. 90.8%, respectively, p=.718; 48 h: 98.5% vs. 95.4%, respectively, p=.496). The median induction-to-abortion interval was also similar for the letrozole and placebo groups (9.6 h vs. 10.6 h, p=.145). All the side effects were comparable between the two groups.
Conclusion: The use of letrozole pretreatment (7.5 mg daily for 3 days) with misoprostol in second-trimester abortion does not significantly improve the abortion rate of the misoprostol-only regimen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2011.03.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seeking abortion medications online: experiences from a mystery client study in Colombia.
BMJ Open
January 2025
Fundación Oriéntame, Bogotá, Colombia.
Objectives: While Colombians gained broad legal access to abortion in 2022, people still lack knowledge about its availability and face variable quality of care at health facilities. This study sought to understand whether online sellers provide the instructions and medication dosages necessary for effective medication abortions.
Design: The study design involved mystery clients contacting sellers identified across websites and social media platforms (Facebook, Instagram, and TikTok) to purchase abortion pills.
Prospective Comparative Study of Misoprostol Alone Versus Mifepristone Plus Misoprostol for Second-Trimester Pregnancy Termination.
J Obstet Gynaecol India
December 2024
DNB Resident, Department of Obstetrics and Gynaecology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan India.
Introduction: MTP has been legalized in India through the Medical Termination of Pregnancy Act, of 1971, which allows pregnancy termination up to 20 weeks. The present study included second-trimester pregnancy terminations and the main aim of the study is to compare the efficacy and safety of tablet mifepristone 24 h before vaginal tablet misoprostol in group-I with vaginal tablet misoprostol alone in group-II as a method of second-trimester pregnancy termination.
Methodology: It was a prospective randomized comparative study conducted at the Department of Obstetrics and Gynaecology, R.
Second trimester medical abortion in acute promyelocytic leukaemia.
BMJ Case Rep
December 2024
Haematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Acute promyelocytic leukaemia (APL) is a highly lethal haematological malignancy. It is rare in pregnancy and may be fatal if not managed promptly and appropriately. A woman in her 20s presented with high-grade fever at 16 weeks of her third pregnancy.
View Article and Find Full Text PDFUterine rupture with induction using misoprostol for intrauterine foetal death in the second trimester: A case report.
Case Rep Womens Health
December 2024
Médecins Sans Frontières-Belgique (OCB), Avenue 7 Février, Grande passe, Port-à-Piment, Haïti.
Uterine rupture is a well-known, life-threatening complication of misoprostol use; the incidence is remarkably low. Herein, we report what seems to be the first documented case of uterine rupture following induction of labour for intrauterine foetal death in the second trimester without a uterine scar. A 40-year-old woman with no history of caesarean section or uterine surgery presented with mild lower abdominal pain and mild genital bleeding.
View Article and Find Full Text PDFEffectiveness and acceptability of a 24-h interval versus a 48-h interval between mifepristone intake and misoprostol administration for in-hospital abortion at 9-20 gestational weeks: an international, open-label, randomised, controlled, non-inferiority trial.
Lancet Glob Health
January 2025
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; WHO Collaborating Centre, Karolinska University Hospital, Stockholm, Sweden.
Background: Optimising management of second-trimester medical abortion is important, as complications increase with gestational age. We aimed to compare a 24-h interval with a 48-h interval between mifepristone intake and misoprostol administration in in-hospital, second-trimester medical abortion for effectiveness and acceptability.
Methods: This open-label, randomised, controlled, non-inferiority trial was conducted at nine hospitals in India, Sweden, Thailand, and Viet Nam among adults undergoing medical abortion for a singleton viable pregnancy at a gestation of between 9 weeks and 20 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!